Abstract:Background: Worldwide, in the absence of standard pediatric prescribing information, clinicians often use medicines in children in a dosage form or for an indication that has not been approved for use. Inadequate clinical trials increase exposure to drugs that lack safety-efficacy data in pediatric population. Hence, off-label and unlicensed drug use must be regarded as a patient safety-issue that is known to be associated with increased risks of adverse drug reactions apart from under- or overdosing due to lack of pharmacokinetic data. This review aims to give an overview of the worldwide reported rates of off-label and unlicensed drug use in different patient populations in pediatric settings, with a brief summary of the related adverse drug reactions (ADRs) and a discussion of the existing regulatory provisions and possible solutions for ensuring safe use of medicines in children. Method: Literature searches were conducted and we included studies that evaluated unlicensed or off-label drug use in various pediatric patient populations. The definition of off-label drug use and unlicensed drug varied between different studies. Results: Fourteen studies from different countries were included in the review and were grouped as: studies conducted in the patients admitted in neonatal intensive care units, in pediatric wards, in hospitalized children and in pediatric outpatient settings. The number of patients studied ranged from 34 in neonatal intensive care units to 355 409 hospitalized children. Many studies reported high rates of off-label (9% to 78.7%) and unlicensed (0.3% to 35%) drug use in different pediatric patient settings. Conclusion: Given the prevalence of unlicensed and off-label drug use, the cooperation of various stakeholders including health professionals, pediatric population and their parents/caregivers, regulatory authorities, and the pharmaceutical industry is integral to instituting individual measures to avoid exposing children to unnecessary risks and avoid depriving them of potentially effective pharmacotherapy. Initiatives to encourage clinical trials for licensing drug use in children by providing market exclusivity and patent extension could aid in bridging the gap between approval and contemporary drug prescribing practices. Enforcement of legislations in the drug development process and subsequent pharmacovigilance could improve the quality of information and accountability of pharmaceutical industry to support and facilitate drug research in children.

Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors

Conducting Drug Treatment Trials in Children: Opportunities and Challenges

Eukaryotic virulence determinants utilize phosphoinositides at the ER and host cell surface.

Pediatric Off-Label and Unlicensed Drug Use and Its Implications

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

Differential diagnosis and treatment of small subdural effusion in children.

Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology

Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges

Pediatric oncology drug development and dosage optimization

Anorectic activity of 2H-4,6-dimethyl-2-[(4-phenylpiperazin-1- yl)methyl]-3-oxo-2,3-dihydroisothiazolo[5,4-b]pyridine.

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Paediatric formulations—part of the repurposing concept?

Rationalizing optimal dosing of phytotherapeutics for use in children: Current status - potential solutions - actions needed

Size and Taste Matters: Recent Progress in the Development of Age-Appropriate Medicines for Children

PHARMACOECONOMICS Affordable orphan drugs: a role for not-for-pro ﬁ t organizations

Innovative study design for paediatric clinical trials

Performing clinical drug trials in children with a rare disease

Development of Paediatric Medicines: Key Risk Factors and Non-clinical Research Programmes

Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children

Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada

Orphan Drug Label Expansions: Analysis Of Subsequent Rare And Common Indication Approvals